BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BioCentury | Feb 15, 2019
Product R&D

A bug about Alzheimer’s

...York, N.Y. Targets tau (MAPT; FTDP-17) - Microtubule-associated protein τ Lauren Martz, Associate Editor Cortexyme Inc. Beta amyloid 42 P. gingivalis lysine gingipain...
BioCentury | Jun 1, 2018

Bacterial brain

...been granted a U.S. patent covering therapeutics that inhibit Porphyromonas gingivalis , including its protease P. gingivalis lysine gingipain...
Items per page:
1 - 3 of 3